Arrowhead Pharmaceuticals Inc

ARWR

Company Profile

  • Business description

    Arrowhead Pharmaceuticals Inc develops medicines using its targeted RNAi molecule, TRiM, platform that uses a natural pathway to silence genes causing disease. It has commercialized Redemplo (plozasiran) as an adjunct to diet to reduce triglycerides (TGs) in adults with Familial Chylomicronemia Syndrome (FCS). Redemplo has received marketing authorization for FCS across the European Union, the USA, Canada, Australia, China, and the United Kingdom. It has several drug candidates in clinical trials ranging from early to late stage, including both partnered and wholly-owned candidates such as Zodasiran, Olpasiran, Fazirsiran, ARO-C3, and others being developed as therapies for various cardiometabolic, pulmonary, liver, neuromuscular, and other conditions. It operates as a single segment.

  • Contact

    177 E Colorado Boulevard
    Suite 700
    PasadenaCA91105
    USA

    T: +1 626 304-3400

    E: [email protected]

    https://www.arrowheadpharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 September 2027

    Employees

    711

Stocks News & Analysis

stocks

Overvalued ASX share has overly ambitious profit target

We think the new profit target is aggressive and unlikely to be met.
stocks

7 undervalued US stocks that crushed earnings

Arista and GE Vernova remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks

Undervalued ASX share hitting on all cylinders

Strong performance across all segments in latest earnings release.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,997.30168.10-1.83%
CAC 408,246.31105.69-1.27%
DAX 4026,266.46332.18-1.25%
Dow JONES (US)51,608.17739.38-1.41%
FTSE 10010,744.36137.19-1.26%
HKSE23,508.17245.67-1.03%
NASDAQ24,509.76626.52-2.49%
Nikkei 22558,860.43801.59-1.34%
NZX 50 Index14,306.963.190.02%
S&P 5007,416.590.000.00%
S&P/ASX 2008,883.20161.50-1.79%
SSE Composite Index3,584.5817.99-0.50%

Market Movers